The Institute of Bioorganic Chemistry offers consumers a medicinal product - the antitumor drug Azacitidine on the basis of a manufacturing agreement, a technology for obtaining a substance for the drug on the basis of a license agreement and is looking for partners to conclude a distribution services agreement.

Antitumor drug Azacitidine for treatment
* myelodysplastic syndrome (MDS) with intermediate-2 or high risk on the IPSS scale;
* acute myeloid leukemia (AML);
* chronic myelomonocytic leukemia without signs of MDS.

The antitumor effect is due to the cytotoxicity of the drug against pathologically altered hematopoietic cells of the bone marrow, its ability to cause DNA hypomethylation.

The technology for the production of the pharmaceutical substance Azacitidine, the dosage form of the drug Azacitidine, regulatory and technical documentation have been developed. Clinical trials of the drug are underway.

The institute has an experimental base for studying the biological activity of the obtained compounds at the cellular level and in tests on animal models. For pilot production of the developed products (hemosorbents, preparations of recombinant enzymes, immunochemical reagents, oxyphitosterols, etc.), 5 experimental production sites have been created at the institute.

The results of fundamental and applied research on methods and means of protecting plants from diseases, insects, weeds, and other unfavorable environmental factors that are safe for humans and the biosphere as a whole were the basis for the development of methods for obtaining new plant growth stimulators, pheromone compositions (pheromones of the codling moth LP -U and mill moth), active ingredients of pesticides (analogs of the herbicide Grasp and insecticide Confidor), formulations of pesticides (herbicides, insecticides, fungicides, etc.).

The created intellectual property of the Institute today consists of patents maintained in force, laboratory technological and experimental industrial regulations, technical specifications, and trademarks. Licensing agreements are in force for the transfer of technologies for the production of immunodiagnostic products, hemosorbents, and pesticides to manufacturers.

Consumers interested in purchasing the anticancer drug Azacitidine under a manufacturing agreement.

Distributors interested in purchasing the anticancer drug Azacitidine under a distribution services agreement.

Partners interested in acquiring technology for obtaining the substance of the anticancer drug Azacitidine under a license agreement.